Inactive Instrument

Baxalta Inc Stock

Stocks

End-of-day quote NYSE Other stock markets
- ^USD	-

16-04-29	Baxalta : Shire jumps as Vyvanse drug helps it to beat earnings forecast	RE
16-04-28	Baxalta : Shire director pay resolution just scrapes though at general meet	RE

16-04-29	Baxalta : Shire jumps as Vyvanse drug helps it to beat earnings forecast	RE
16-04-28	Baxalta : Shire director pay resolution just scrapes though at general meet	RE
16-02-11	Baxalta : Drugmaker Shire delivers earnings beat amid deal-making push	RE
16-01-12	Baxalta : Shire says internal synergy goals from Baxalta deal higher	RE
16-01-11	Baxalta : Drugmaker Shire buys Baxalta for $32 billion after six-month pursuit	RE
16-01-11	Baxalta : Drugmaker Shire buys Baxalta for $32 billion after six-month pursuit	RE
16-01-07	Baxter : Shire, Baxalta to announce merger as soon as Monday: sources	RE
15-12-22	Shire : closer to deal to buy Baxalta - sources (Exclusive)	RE
15-12-22	Baxter : Exclusive - Shire closer to deal to buy Baxalta: sources	RE
15-11-24	Baxalta : Exclusive: Shire prepares to make new bid for Baxalta - source	RE
15-11-02	Baxalta : Shire to buy Dyax for $5.9 billion, still wants Baxalta	RE
15-11-02	Baxalta : Shire to buy Dyax for $5.9 billion, still wants Baxalta	RE
15-10-27	Baxter : to cut 1,400 jobs worldwide to boost profits	RE

16-06-03	Baxalta : Shire Completes Combination With Baxalta Creating the Global Leader in Rare Diseases and Highly Specialized Conditions	PR
16-05-27	Baxalta : CORRECTING and REPLACING Baxalta Shareholders Vote to Approve Combination	BU
16-05-26	Baxalta : OncoResponse Secures Investment from Baxalta	BU
16-05-25	Baxalta : Reports Positive Phase 1 Results for BAX 930, Investigational Recombinant ADAMTS13 to Treat Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)	BU
16-05-24	Baxalta : Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist Program from Astellas Pharma Inc.	BU

16-01-12	Wall Street termine dans le désordre une séance volatile
16-01-11	Alcoa : Wall Street termine dans le désordre une séance volatile
16-01-11	Wall Street termine dans le désordre une séance volatile
16-01-11	Baxalta : Shire met la main sur Baxalta pour 32 milliards de dollars
16-01-11	Baxalta : La valeur du jour à Wall Street - BAXALTA racheté par Shire pour 32 milliards de dollars

Manager	Title	Age	Since
Fabien Dubois PSD	President	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	+0.14%	+2.08%	+20.70%	-21.38%	62.54B
UCB	+0.68%	-4.88%	+59.03%	+198.69%	55.22B
SAMSUNG BIOLOGICS CO.,LTD.	+0.08%	+33.30%	+33.30%	+33.30%	40.9B
CSL LIMITED	+0.51%	+3.73%	-55.37%	-62.46%	35.99B
BIOGEN INC.	+1.22%	+2.12%	+56.72%	-32.49%	28.88B
MODERNA, INC.	+1.78%	+23.14%	+121.64%	-54.42%	21.98B
INCYTE CORPORATION	+0.56%	-4.82%	+45.78%	+62.45%	19.93B
INNOVENT BIOLOGICS, INC.	-2.03%	+0.67%	-2.92%	+110.25%	16.95B
SWEDISH ORPHAN BIOVITRUM AB	+1.39%	+0.28%	+55.45%	+100.09%	15.87B
Average	+0.48%	+2.08%	+37.15%	+37.12%	33.14B
Weighted average by Cap.	+0.46%	+1.25%	+33.45%	+37.94%